Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration, the Biden campaign and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
Featured Prescription Drugs Resources
KFF Health Tracking Poll – October 2019: Health Care In The Democratic Debates, Congress, And The Courts
This poll examines health care issues in the Democratic presidential primary , government negotiation of prescription drug prices, party trust on health care, Medicare-for-all, and the pending Texas v. US lawsuit affecting the Affordable Care Act and pre-existing condition protections.
Poll Finding See More
Related Prescription Drugs Resources
- Assessing Drug Price Increases in Medicare Part D and the Implications of Inflation Limits
- 10 FAQs on Prescription Drug Importation
- Pricing and Payment for Medicaid Prescription Drugs
- Management and Delivery of the Medicaid Pharmacy Benefit
- Understanding the Medicaid Prescription Drug Rebate Program
- A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries
- Kaiser Health News Coverage of Prescription Drug Issues
- What are the recent and forecasted trends in prescription drug spending?
- How Will The Medicare Part D Benefit Change Under Current Law and Leading Proposals?
- Medicaid’s Prescription Drug Benefit: Key Facts
- Prescription Drug Rebates, Explained
- Who is Most Likely to Have High Prescription Drug Costs?
- Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
- 10 Essential Facts About Medicare and Prescription Drug Spending
- Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs, 2014-2017
- How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?
What’s the Latest on Prescription Drug Proposals from the Trump Administration, Congress, and the Biden Campaign?
This slideshow explains the similarities and differences among major proposals to lower prescription drug costs introduced by the Trump Administration, members of Congress, and the Biden campaign.
Slideshow See More
- view as grid
- view as list
For a number of years, Governors and other state policymakers have maintained that Medicare – rather than state Medicaid programs – should play the key role in providing prescription drug coverage to Medicare beneficiaries, including those who also qualify for Medicaid because they are impoverished and/or have extensive health care…Issue Brief Read More
Summary of Low-Income Subsidy Program in Final Medicare BillThis presentation summarizes the dual eligible population, the low-income provisions of the new Medicare drug benefit and discusses the impact on state Medicaid programs.Presentation Slides (.pdf)Event Read More
Prescription Drug Coverage for Medicare Beneficiaries: A Summary of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
This document, prepared by Health Policy Alternatives, Inc., provides a detailed summary of the prescription drug provisions of the Medicare legislation (P.L. 108-173) signed by the President on December 8, 2003.Report (.pdf)Report Read More
This Briefing Note explores the issues presented for the design and administration of a new Medicare drug benefit by dually eligible nursing facility residents.Issue Paper (.pdf)Issue Brief Read More
Standard Medicare Drug Benefit, 2006Out-of-pocket drug spending for Medicare beneficiaries under the standard Medicare drug benefit described in the Medicare Modernization Act of 2003. Chart (.pdf)Report Read More
Prescription Drug Coverage for Medicare Beneficiaries: A Side-by-Side Comparison of S. 1 and H.R. 1 and the Conference Agreement H.R. 1
This document, prepared by Health Policy Alternatives, Inc., provides a detailed side-by-side comparison of the prescription drug provisions of the Conference Agreement (H.R. 1) passed by the House and Senate in November 2003 and the House (H.R. 1) and Senate (S. 1) Medicare proposals passed in June 2003.Report (.pdf)Report Read More
States’ Concerns About the Medicare Drug Debate and the Fiscal Impact of Shifting the Cost of Dual Eligible Care
As the U.S. Congress continues to search for an agreement on the form of a Medicare prescription drug benefit, the Commission has two new reports related to the debate. One new publication reports on findings from an October 26 discussion with state Medicaid officials on the implications of a Medicare…Issue Brief Read More
This issue paper provides state-level estimates on spending on dual eligibles and illustrates the fiscal effects of scenarios where the federal government assumes the cost of prescription drugs, Medicare premiums, acute care, and long-term care for this population.Issue Paper (.pdf)Issue Brief Read More
Coordinating Medicaid and Medicare Prescription Drug Coverage: Findings from a Focus Group Discussion with Medicaid Directors
This publication reports on the findings from an October 26 focus group discussion with state Medicaid officials on the implications of a Medicare drug benefit for states and dual eligibles.Report (.pdf)Report Read More
Designing a Medicare Drug Discount Card: Implications of Policy Choices for Medicare Beneficiaries and Plan Sponsors
This report analyzes key issues surrounding the implementation of a Medicare-endorsed prescription drug discount card program. Medicare prescription drug discount cards have been proposed as a short-term strategy for lowering prescription drug costs for Medicare beneficiaries. The report considers the implications for both discount card sponsors and beneficiaries of alternative…Report Read More